Is Adenosine registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 6 valid registrations of Adenosine, including ADENOCOR 6MG-2ML VIAL (3 mg/ml, Solution for injection, SAR 153.45); ADENOHARDT 30MG/10ML SOLUTION FOR INFUSION (3 mg/ml, Solution for injection, SAR 339.40); ADENOHARDT 6MG/2ML SOLUTION FOR INFUSION (3 mg/ml, Solution for injection, SAR 140.50); Cardesine 6mg/2ml Solution for Injection (3 mg/ml, Solution for injection, SAR 122.20); REVARDIA (3 mg/ml, Solution for injection, SAR 156.15).

Is Adenosine approved by the US FDA?

Drugs@FDA lists 23 application product lines for Adenosine, including ADENOSINE (Prescription); ADENOSINE (Prescription); ADENOSINE (Prescription); ADENOSINE (Prescription); ADENOSINE (Prescription).

Active substance

Adenosine

SFDA 6
US FDA 23
Health Canada 3

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
ADENOCOR 6MG-2ML VIAL	3 mg/ml	Solution for injection · Intravenous use	6 Vial	SAR 153.45	NCE · Prescription	AVENTIS PHARMA LIMITED	Valid
ADENOHARDT 30MG/10ML SOLUTION FOR INFUSION	3 mg/ml	Solution for injection · Intravenous use	6 Vial	SAR 339.40	NCE · Prescription	WOCKHARDT UK LIMITED	Valid
ADENOHARDT 6MG/2ML SOLUTION FOR INFUSION	3 mg/ml	Solution for injection · Intravenous use	6 Vial	SAR 140.50	Generic · Prescription	WOCKHARDT UK LIMITED	Valid
Cardesine 6mg/2ml Solution for Injection	3 mg/ml	Solution for injection · Intravenous use	6 Vial	SAR 122.20	Generic · Prescription	MS Pharma Saudi (MSPS)	Valid
REVARDIA	3 mg/ml	Solution for injection · Intravenous use	6 Vial	SAR 156.15	Generic · Prescription	Tabuk Pharmaceutical Manufacturing Company	Valid
Xoria	3 mg/ml	Solution for injection · Intravenous use	6 Ampoule	SAR 110.00	Generic · Prescription	Jazeera Pharmaceutical Industries (JPI)	Valid

Indications — CHI Daman Drug Formulary

ANESTHESIA-SUPPORTIVE AGENTS/ CARDIAC ARREST, CARDIOVASCULAR EMERGENCIES AND/OR DYSRHYTHMIAS; ARRHYTHMIA; SUPRAVENTRICULAR TACHYCARDIA

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
ADENOSINE	3MG/ML	injectable · injection	HIKMA PHARMS	Prescription	16 Jun 2004
ADENOSINE	3MG/ML	injectable · injection	HIKMA PHARMS	Prescription	16 Jun 2004
ADENOSINE	3MG/ML	injectable · injection	FRESENIUS KABI USA	Prescription	27 Apr 2005
ADENOSINE	3MG/ML	injectable · injection	GLAND PHARMA LTD	Prescription	14 Jun 2007
ADENOSINE	3MG/ML	injectable · injection	RISING	Prescription	31 Oct 2008
ADENOSINE	3MG/ML	injectable · injection	MYLAN LABS LTD	Prescription	13 May 2009
ADENOSINE	60MG/20ML (3MG/ML); 90MG/30ML (3MG/ML)	solution · intravenous	MEITHEAL	Prescription	29 Aug 2013
ADENOSINE	60MG/20ML (3MG/ML); 90MG/30ML (3MG/ML)	solution · intravenous	MYLAN ASI	Prescription	28 Mar 2014
ADENOSINE	60MG/20ML (3MG/ML); 90MG/30ML (3MG/ML)	solution · intravenous	AVET LIFESCIENCES	Prescription	15 Sep 2014
ADENOSINE	60MG/20ML (3MG/ML); 90MG/30ML (3MG/ML)	solution · intravenous	RISING	Prescription	2 Oct 2014
ADENOSINE	60MG/20ML (3MG/ML); 90MG/30ML (3MG/ML)	solution · intravenous	EUGIA PHARMA	Prescription	2 Nov 2017
ADENOSINE	60MG/20ML (3MG/ML); 90MG/30ML (3MG/ML)	solution · intravenous	FRESENIUS KABI USA	Prescription	27 Nov 2017
ADENOSINE	3MG/ML	injectable · injection	GLAND	Prescription	16 Feb 2018
ADENOSINE	3MG/ML	injectable · injection	FRESENIUS KABI USA	Prescription	16 Apr 2018
ADENOCARD	3MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	injectable · injection	ASTELLAS	Discontinued	30 Oct 1989
ADENOSCAN	60MG/20ML (3MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons; 90MG/30ML (3MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	solution · intravenous	ASTELLAS	Discontinued	18 May 1995
ADENOSINE	3MG/ML	injectable · injection	HIKMA	Discontinued	16 Jun 2004
ADENOSINE	3MG/ML	injectable · injection	TEVA PHARMS USA	Discontinued	16 Jun 2004
ADENOSINE	3MG/ML	injectable · injection	TEVA PHARMS USA	Discontinued	31 Jul 2008
ADENOSINE	3MG/ML	injectable · injection	AM REGENT	Discontinued	28 Apr 2009
ADENOSINE	3MG/ML	injectable · injection	WOCKHARDT	Discontinued	20 Jul 2009
ADENOSINE	3MG/ML	injectable · injection	PHARMOBEDIENT	Discontinued	21 Mar 2014
ADENOSINE	60MG/20ML (3MG/ML); 90MG/30ML (3MG/ML)	solution · intravenous	HOSPIRA	Discontinued	24 Mar 2014

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
ADENOSINE INJECTION	02267659	3 MG / ML	SOLUTION · INTRAVENOUS	FRESENIUS KABI CANADA LTD
ADENOSINE INJECTION	02457474	3 MG / ML	SOLUTION · INTRAVENOUS	FRESENIUS KABI CANADA LTD
ADENOSINE INJECTION	02457482	3 MG / ML	SOLUTION · INTRAVENOUS	FRESENIUS KABI CANADA LTD

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.